Dec 02, 2010 (Datamonitor via COMTEX) --
Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in development of monoclonal antibody-based drugs, has initiated an investigator-sponsored trial, or IST, for patients with advanced hepatocellular carcinoma, or HCC, or liver cancer.
This phase I/II trial will treat patients with Peregrine's investigational monoclonal antibody bavituximab in combination with sorafenib.
Currently, Peregrine's bavituximab is being evaluated in combination with chemotherapy in multiple phase II trials in non-small cell lung cancer and advanced breast cancer, as well as a phase Ib trial for hepatitis C virus (HCV) and HIV coinfection.
"In prior studies, bavituximab has demonstrated broad therapeutic potential in multiple oncology indications," said Marvin R. Garovoy, M.D., head of clinical science at Peregrine Pharmaceuticals. "Our IST program is designed to provide valuable clinical data on bavituximab's potential use in different therapeutic combinations and indications. We also expect to further clarify details of bavituximab's multiple mechanisms of action, and to identify specific biomarkers that could ultimately help to measure and predict bavituximab's potential anti-tumor and immunostimulatory effects. We look forward to collaborating with Dr Yopp and his team, as well as other investigators who have applied for our program."
Source
No comments:
Post a Comment